Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (ILC) or mixed invasive ductal and lobular carcinoma (mixed)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouabbi, Jason A., Raghavendra, Akshara Singareeka, Bassett, Roland L., Hassan, Amy, Tripathy, Debu, Layman, Rachel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768132/
https://www.ncbi.nlm.nih.gov/pubmed/36539444
http://dx.doi.org/10.1038/s41523-022-00499-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768132/
https://www.ncbi.nlm.nih.gov/pubmed/36539444
http://dx.doi.org/10.1038/s41523-022-00499-7

Ejemplares similares